rea-medicrea-5a4276cf1b952a23a2381b1b66a95324546377b474c62e264272afb9a3c02711.jpg

Medicrea Releases First Quarter Sales For 2017

Posted On April 17, 2017 By OrthoSpineNews In Financial /  

April 13, 2017

LYON, France & NEW YORK–(BUSINESS WIRE)–The Medicrea Group (Alternext Paris: FR0004178572 – ALMED), worldwide leader pioneering the development and manufacture of personalized analytical services and implant solutions for the treatment of complex spinal conditions, publishes its sales for the 1st quarter of 2017.

(€ millions) 2016 2017 Variation
1st Quarter 7.0 7.0 –
Changes in exchange rates had no material impact on year to year comparison

During the 1st quarter of 2017, Medicrea continued the major corporate restructuring initiated in 2016 with the permanent closure of the original La Rochelle site and the relocation of all manufacturing operations to the new ultra-modern facility in Rillieux-la-Pape, near Lyon. The Company is now well positioned to respond to new market opportunities.

This transfer involved a large part of the Company’s resources, which were also heavily involved in two successful certification audits conducted by the FDA (Food and Drug Administration) for the marketing of implants in the United States and by LNE/G-MED (Working Group for the Evaluation of Medical Devices) for renewal of the CE marking.

Against this backdrop, Q1 sales remained stable compared to the same period of the previous year at €7 million.

Adoption of the Company’s UNiD™ technology continued over Q1 2017 with a 38% increase in surgeries utilizing patient-specific UNiD™ Rods in the United States compared to the same quarter of 2016.

Events: ISASS 2017

Medicrea will be showcasing UNiD™ Adaptive Spine Intelligence and patient-specific implants this week at Booth #420 of the 17th Annual Conference of The International Society for the Advancement of Spine Surgery (ISASS) held in Boca Raton, Florida from April 12 to 14, 2017. On Thursday, April 13th, Medicrea technology, including early clinical results with UNiD™ 3D-printed patient-specific vertebra, features twice in the conference’s official scientific program in Presentation 483 and Presentation 456. More information on the event is available here.

Next publication: Sales for the 1st half of 2017: July 11, 2017, after market.

About Medicrea (www.medicrea.com)

Medicrea specializes in bringing pre-operative digital planning and pre and post-operative analytical services to the world of complex spine. Through the lens of predictive medicine, Medicrea leads the design, integrated manufacture, and distribution of 30+ FDA approved implant technologies, utilized in over 100k spinal surgeries to date. Operating in a $10 billion marketplace, Medicrea is an SME with 160 employees worldwide, which includes 55 at its USA Corp. subsidiary in NYC. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants.

By leveraging its proprietary software analysis tools with big data and deep learning technologies supported by an expansive collection of clinical and scientific data, Medicrea is well-placed to streamline the efficiency of spinal care, reducing procedural complications and limiting time spent in the O.R.

For further information, please visit: www.medicrea.com

Connect with Medicrea:
FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE

Medicrea is listed on
ALTERNEXT Paris ISIN: FR 0004178572– Ticker: ALMED

Contacts

Medicrea
Denys SOURNAC
Founder, Chairman and CEO
dsournac@medicrea.com
or
Fabrice KILFIGER
Chief Financial Officer
fkilfiger@medicrea.com
Tel: +33 (0)4 72 01 87 87
or
Media
Russell WARD for Medicrea
russell@theconfluencegroup.com
Tel: +1 310 424 8356

Read More

Invibio: Around 9 Million Implanted Devices Worldwide Now Using PEEK-OPTIMA™ Polymer

Posted On April 17, 2017 By OrthoSpineNews In Spine /  

THORNTON CLEVELEYS, UK (PRWEB) APRIL 13, 2017

The number of implanted devices using PEEK-OPTIMA™ polymer has now increased to around nine million, worldwide. Pioneering developments and close collaboration with device companies, as well as assembling and sharing early clinical results with the medical community, have helped medical-grade PEEK innovator Invibio to deliver this progress. The dedicated medical “International PEEK Meeting” taking place in Washington DC, USA, April 27-28, is expected to provide additional impetus through the presentation of leading-edge research in the PEEK biomaterial polymer technology and its clinical application.

“Although it has a history of over 15 years as a biomaterial, PEEK continues to be used to actively innovate in the quest for improved patient care. The meeting will focus on the latest advances in orthopedics, spine, trauma, and dentistry applications. It is important that the medical community has access to latest updates and developments”, emphasizes Steve Kurtz, Ph.D., Implant Research Center, Drexel University (Philadelphia, PA, USA), and conference organizer, in the run-up to the 3rd International PEEK Meeting.

Need to offer improved options for surgeons and ultimately patients Kurtz continues: “I think the most interesting part of the event is the combined regulatory, scientific, and clinical audience. We all need to understand not only the technical aspects about PEEK and device characteristics but to help patients and translate these advances to the clinic as quickly as possible. It is important that we understand this new type of implant biomaterial. The focus of the upcoming meeting is going to be on the clinical understanding of how PEEK performs in new applications along with additive manufacturing and composites of PEEK implants, and understanding how to address the regulatory science questions in this area.”

The Implant Research Center at Drexel University and Exponent, Inc. chairs the meeting and invited the medical community to submit abstracts, which were then evaluated by a scientific committee for inclusion in the program either as a podium presentation or poster.

PEEK polymer based solutions: may offer distinct advantages compared to metal alternatives

One of the highlight presentations for example investigated whether locking screw fixation in carbon fibre reinforced PEEK (CFR-PEEK) composite plates is mechanically equivalent to stainless steel plates.1)

The composite biomaterial CFR-PEEK is gaining popularity for fracture fixation due to its high fatigue strength, favorable modulus of elasticity, and radiolucency. This study assessed the mechanical stability of locking screws used in CFR-PEEK proximal humerus plates compared with those used in stainless steel plates. Based on this study, CFR-PEEK proximal humerus locking plates provide comparable or superior locking screw fixation strength compared to traditional stainless steel locking plates.

Over 15 years of proven history in clinical use of PEEK has made its mark on the medical world

From the initial commercial introduction of PEEK as a biomaterial Invibio Biomaterial Solutions has, for more than 15 years, pioneered advances in the application of high-performance PEEK-based implantable polymers such as PEEK-OPTIMA. Corresponding to the company´s mission to facilitate medical-device innovation by providing new solutions and support for PEEK-related research, Invibio is sponsoring this cross-sector forum for sharing and discussing those latest advances that are both independent and international in scope.

Further details on the upcoming “3rd International PEEK Meeting”

Topics

  • Advances in the additive manufacturing of PEEK and its composites
  • Innovations in orthopedic bearings
  • Bioactive PEEK composites
  • Advances in spinal rods and artificial disc applications
  • Advances in formulations for dental, trauma, and arthroscopic implants
  • Structural composites and woven-fiber applications
  • Advances in the biologic aspects of wear debris

Scientific and Organizing Committee of the 3rd International PEEK Meeting:

  • Steven Kurtz, Ph.D., Implant Research Center, Drexel University and Exponent, Inc.
  • Joanne Tipper, Ph.D., Leeds University
  • Katherine Kavlock, Ph.D., US FDA CDRH (Center for Devices and Radiological Health)
  • John Bowsher, Ph.D., US FDA CDRH

Save the date and register

  • Thursday & Friday, April 27-28th, 2017 in Washington DC at The Cosmos Club.

REFERENCES
1.    Hak, David J. et al. (2017): Is locking screw fixation in carbon fibre composite plates mechanically equivalent to stainless steel plates? Presentation during 3rd International PEEK Meeting 2017

About Invibio Biomaterial Solutions
Invibio, a Victrex plc company, is a global leader in providing high performance biomaterial solutions to medical device manufacturers. The company provides PEEK-OPTIMA™ polymers, advanced technical research and support and manufacturing of components for spine, trauma and orthopaedic medical segments for the development of long implantable medical devices. Today, Invibio’s PEEK-OPTIMA™ polymers are used in ~9 million implanted devices worldwide.

INVIBIO™, PEEK-OPTIMA™, INVIBIO BIOMATERIAL SOLUTIONS™ are trademarks of Victrex plc or its group companies. All rights reserved.

About Victrex plc
Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of automotive, aerospace, energy, electronics and medical. Every day, millions of people use products and applications, which contain our materials – from smart phones, aeroplanes and cars to oil and gas operations and medical devices. With over 35 years’ experience, we develop world leading solutions in PEEK- and PAEK-based polymers, semi-finished and finished parts which shape future performance for our customers and our markets, and drive value for our shareholders. Find out more at http://www.victrexplc.com or http://www.victrex.com

Copyright ©2017 Invibio Ltd.

Read More
Amendia-Tradeshows_600x400.jpg

Amendia Announces Acquisition of Spinal Elements

Posted On April 13, 2017 By OrthoSpineNews In Spine /  

MARIETTA, GA (PRWEB) APRIL 13, 2017

Leading spinal solutions provider Amendia, Inc. is pleased to announce the acquisition of Spinal Elements, Inc., a Carlsbad, California-based corporation.

“The acquisition of Spinal Elements brings a wealth of talent and a portfolio of exciting new products to the Amendia organization,” stated Chris Fair, CEO and President of Amendia, Inc. “The combination of these two companies solidifies our position as one of the fastest growing and most comprehensive spine companies in the marketplace today,” continued Fair.

Jason Blain, President of Spinal Elements, added, “Together, the company moving forward will provide a robust portfolio of spine products featuring titanium-coated PEEK interbody technology. We are thrilled about what lies ahead.”

Spinal Elements’ clinically proven Ti-Bond® porous titanium coating and upcoming product launches of the Lucent XP expandable cage and the Clutch interspinous process device, will complement Amendia’s recent launches of the Overwatch pedicle screw system, Syzygy reduction screw system and the Ceres cervical product lines.

Media inquiries should be directed to Steve McAllister, EVP and Chief Financial Officer at 770-575-5201.

About Amendia

Headquartered in a state-of-the-art manufacturing facility in Marietta, Georgia, Amendia is a leading designer, developer, manufacturer and marketer of medical devices used in spinal surgical procedures. Amendia’s mission is to exceed surgeon and patient expectations by creating balanced solutions with disruptive technologies for medical devices paired with biologics and instrumentation. Amendia’s vertically-integrated strategy focuses on improving surgical outcomes and the lives of patients with spinal disorders. For more information, please visit http://www.amendia.com.

About Spinal Elements

Spinal Elements, headquartered in Carlsbad, CA, is a spine technology company for spine surgeons who demand innovative, extremely high quality surgical solutions. From the company’s early work which helped make PEEK commonplace throughout the spine industry to recent advancements in Ti-Bond® porous titanium coated PEEK interbody implants and controlled delivery technology, Spinal Elements has built a reputation for being trustworthy, innovative and different. The company is focused on the development and marketing of progressive spinal treatment options and markets a complete portfolio of advanced spinal implant technologies. Additionally, the company distributes Hero® Allograft, the net proceeds from which are donated to charities benefitting children with life-threatening medical conditions. The company recently launched a warranty program for its Ti-Bond technology based on the success of over 10,000 devices implanted. For more information, please visit http://www.spinalelements.com.

Read More
la-fi-fda-scope-cleaning-20150804-1.jpg

Additive Orthopaedics Announces FDA Clearance of their Locking Lattice Plating System for the Global Extremities Market

Posted On April 13, 2017 By OrthoSpineNews In Regulatory /  

LITTLE SILVER, N.J., April 13, 2017 /PRNewswire/ — Additive Orthopaedics, LLC., an early stage orthopaedic device company, today announced that is has received FDA 510(k) clearance for its 3D printed Locking Lattice Plating System, to address stabilization and fusion of fractures, osteotomies, and arthrodesis of small bones.

According to Greg Kowalczyk, President of Additive Orthopaedics, “We are excited to be one of the first companies to leverage the geometric flexibility, clinical advantages and manufacturing cost benefits of additive manufacturing in the orthopaedic plating market.  These plates can be implanted either alone with locking or non-locking screws, or in conjunction with our 3D printed bone segments through the use of a connection screw. This allows the surgeon to mix and match any wedge and plate combination for various deformities, complex revisions, or other limb salvage procedures.”

This is the Company’s third 510(k) clearance leveraging additive manufacturing and fifth product line, which includes their 3D printed core products, biologics, and customs for limb salvage and complex revision cases.  Surgeons have implanted over 300 of their individual devices since the first full commercial product launch at the end of 2016.  The Company has recently closed a Series A Round of $1M.

About Additive Orthopaedics, LLC.
Additive Orthopaedics is an early stage orthopaedic company focused on the integration of advanced manufacturing and biologics for the benefit of a better patient outcome.

Contact:
Greg Kowalczyk
732.882.6633
greg@additiveorthopaedics.com

 

SOURCE Additive Orthopaedics, LLC.

Read More
46210783_l-1-e1453303297665.jpg

Inspired Spine Achieves Milestone of 500 Minimally Invasive OLLIF Procedures

Posted On April 13, 2017 By OrthoSpineNews In Spine, Top Stories /  

MINNEAPOLIS, MINNESOTA (PRWEB) APRIL 12, 2017

Inspired Spine, a Minnesota-based spine surgery innovation company, has reached the milestone of completing 500 Oblique Lateral Lumbar Interbody Fusion (OLLIF) procedures. This truly minimally invasive surgical technique is revolutionizing the performance of lumbar interbody fusions by delivering superior outcomes including substantially less patient recovery time and minimal blood loss, while requiring a procedure duration as short as 30 minutes.

The OLLIF procedure is a minimally invasive lumbar fusion technique that employs an incision of 15 millimeters, produces 80% less blood loss than a traditional fusion, and requires no muscle detachment to access the disc space. After a surgeon learns this technique, the procedure requires less than one third of the time required to perform a traditional fusion procedure, decreasing the patient’s anesthesia risk and increasing OR throughput efficiency.

Remarkably, many patients are ambulatory within two hours after surgery and are often discharged the same day. No infections have occurred during the first 500 procedures.

Numerous studies have been and are currently being performed during the journey to the 500th procedure. One study that has been published in the peer reviewed journal Cureus and presented at several national meetings is “Economic Performance of Oblique Lateral Lumbar Interbody Fusion (OLLIF) with a Focus on Hospital Throughput Efficiency.” This study demonstrated that due to its substantially reduced surgical time and shorter required hospital stay duration, the OLLIF procedure has saved hospitals an average of $9500 per case while improving patient outcomes.

Inspired Spine has also developed two derivative lumbar fusion techniques from the OLLIF approach: 1) MIS-DLIF and 2) MIS-DTIF. MIS-DLIF enables minimally invasive lumbar fusions to be successfully performed at L5-S1, overcoming the obstacles presented by the ala of the sacrum and the iliac crest. MIS-DTIF enables minimally invasive fusion of the thoracic levels of the spine, eliminating the risks associated with traditional thoracic approaches.

Additionally, OLLIF, MIS-DLIF and MIS-DTIF have been employed to successfully treat adult degenerative scoliosis for several of the first 500 patients.

Said Chief Medical Officer Hamid Abbasi MD, “Inspired Spine’s mission is to improve patient outcomes by substantially upgrading the surgical standard of care to that which is truly minimally invasive to deliver maximum improvements to each patient. Therefore, our team developed the capability to effectively employ the OLLIF and its derivative techniques throughout the lumbar and thoracic spine. Our data from the 500 procedures demonstrates and documents exceptional outcomes with minimal complications!”

Inspired Spine offers regular training sessions for surgeons nationwide including cadaver labs and on-site proctoring. Additionally, patients can locate an Inspired Spine Certified physician for treatment by visiting InspiredSpine.com.

About Inspired Spine

Inspired Spine, a Minnesota-based advanced minimally invasive spinal surgery technology developer, has introduced and performed over 500 procedures using revolutionary new technologies and procedures in advanced minimally invasive systems. These new procedures are transforming how spinal surgeries are approached and can replace more traditional “open” spinal fusion surgeries.

Inspired Spine is focused on the development of advanced minimally invasive surgical techniques, procedures and other health care technology to minimize or eliminate the physical and economic risks and discomfort that are created by the daily struggles of enduring back pain and its physical limitations. Learn more at http://inspiredspine.com/.

Contact for Inspired Spine:
David Greene, 602-677-8981
dgreene(at)theusleadnetwork.com

Read More
bdd2d8b9-4a02-46cd-a935-5c297c10c252-large.jpeg

United Orthopedic Corporation Receives U.S. FDA Clearance For Company’s Polyethylene Knee Insert

Posted On April 13, 2017 By OrthoSpineNews In Regulatory /  

IRVINE, Calif., April 12, 2017 /PRNewswire/ — United Orthopedic Corporation (UOC), a leading international designer, manufacturer and distributor of innovative orthopedic implants and instruments, today announced that the U.S. Food and Drug Administration (FDA) cleared its E-XPE™ polyethylene knee insert. The knee insert is designed to provide patients with knee replacements with reduced risk of oxidation.1

“Clearance of our E-XPE™ polyethylene knee insert represents an important milestone in our knee portfolio,” said Calvin Lin, President of United Orthopedic Corporation USA. “Oxidation continues to be a concern for surgeons. The E-XPE™ polyethylene is resistant to oxidation and performs extremely well with respect to abrasive wear resistance.”

The E-XPE™ is the new generation of highly cross-linked polyethylene blended with 0.1 percent (w/w) vitamin E to enhance wear resistance without compromising oxidative stability and mechanical properties.

UOC’s vertically integrated manufacturing process is unique, enabling the company to control the production cycle of their implants, from initial design to distribution in each of its manufacturing facilities. By doing so, UOC is capable of ensuring a stable, quality product supply and a remarkable level of customization to meet the needs of patients.

More than 600,000 knee replacements are performed each year in the United States.2

About United Orthopedic Corporation

United Orthopedic Corporation (UOC) is a leading international designer, manufacturer, and distributor of innovative, regulatory compliant orthopedic implants and instrument sets used by surgeons around the globe. UOC’s offering includes a flexible range of clinically proven solutions used to perform total hip/knee replacements and revisions, plus clinical education, service and support for surgeons and hospital staff. UOC operates Quality Management Systems (QMS) that comply with ISO 9001/13485, FDA, and CE requirements. For more information about United Orthopedic Corporation, visit www.uocusa.com.

Media Contact
Erich Sandoval
Lazar Partners Ltd.
Tel: +1 917-497-2867
Email: esandoval@lazarpartners.com

_________________________
1 Bellare, A. et al. Journal of Applied Polymer Science (2016). Oxidation Resistance and Abrasive Wear Resistance of Vitamin E Stabilized Radiation Crosslinked Ultra-High Molecular Weight Polyethylene, DOI:10.1002/APP.44125.
2 American Academy of Orthopedic Surgeons website. Beyond Surgery Day:
The Full Impact of Knee Replacement. Accessed April 10, 2017 from: http://www.anationinmotion.org/value/knee.

SOURCE United Orthopedic Corporation

Related Links

http://www.uocusa.com

Read More
index.6jpg-lightbox.jpg

EOS Imaging Reports 34% Revenue Growth for the First Quarter of 2017

Posted On April 13, 2017 By OrthoSpineNews In Financial /  

April 12, 2017

PARIS–(BUSINESS WIRE)–EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible for PEA-PME savings schemes in France), the pioneer in 2D/3D orthopaedic medical imaging, today announced its consolidated revenue for the first quarter ended March 31, 2017.

Marie Meynadier, Chief Executive Officer of EOS imaging, said, “We delivered a quarter of strong growth, building on our positive momentum in EMEA, including a first sale in Israel and significant sales in the United Kingdom. This also reflects an excellent momentum in the Asia-Pacific region, driven by market approval in China obtained in 2016.”

€ millions Q1 2017 Q1 2016
Equipment sales 5.47 4.09
As a % of total revenues 77% 77%
Sales of maintenance 1.40 0.99
As a % of total revenues 19% 18%
Sales of consumables and services 0.26 0.24
As a % of total revenues 4% 5%
Total revenues 7.13 5.33
Unaudited data
  • First-quarter 2017 revenue up 34% to €7.13 million

The Company sold 14 EOS® platforms in the first quarter of 2017, compared to 10 in the same period last year. Revenues from sales of equipment totalled €5.47 million, an increase of 34%.

Sales of maintenance contracts increased by 41% to €1.40 million against €0.99 million in the first quarter of 2015. This reflects the continued increase in the installed base of EOS systems and an associated high contract subscription rate after warranty.

Sales of consumables and services were €0.26 million in the first quarter of 2017 versus €.024 million in the first quarter of 2016.

  • The strong growth in sales was driven by continued expansion in EMEA and Asia-Pacific
€ millions Q1 2017 Q1 2016
EMEA 3.21 2.45
North America 2.48 2.85
Asia-Pacific 1.44 0.03
Total revenues 7.13 5.33
Unaudited data

EOS reported continued sales momentum in EMEA, generating revenue of €3.21 million, an increase of 31% compared to the same period last year. This included strong sales in the United Kingdom as well as a first sale in Israel.

Sales in North America were €2.48 million, a decrease of 13% compared to the first quarter of 2016, which included particularly high sales in this region.

Sales in the Asia-Pacific region were €1.44 million. This largely reflects sales in China following regulatory approval in 2016.

  • Chief Financial Officer Transition

Anne Renevot, EOS imaging’s Chief Financial Officer, will leave the Company at the end of April to pursue other professional interests. The EOS imaging financial team, composed of 5 employees, will be led by an interim-CFO until the recruitment of a permanent CFO is completed. “I would like to thank Anne for her professionalism, commitment and contribution to the development of the Company. I wish her as much success in her new career as she had in our collaboration,” said Marie Meynadier.

For more information, please visit www.eos-imaging.com.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris

ISIN: FR0011191766 – Ticker: EOSI

About EOS imaging

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2016 revenues of €30.8 million and employs 132 people at December 2016, including an R&D team of 43 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.

Next press release: 2017 First-half sales on July 18, 2017 (after the market close)

Contacts

EOS imaging
Anne Renevot, +33 (0)1 55 25 61 24
CFO
investors@eos-imaging.com
or
NewCap
Financial communication and investor relations
Pierre Laurent / Valentine Brouchot
+33 (0)1 44 71 94 96
eosimaging@newcap.eu
or
The Ruth Group (US)
Press relations
Joanna Zimmerman, 646-536-7006
jzimmerman@theruthgroup.com

Read More
slide3-1.jpg

NuVasive To Feature Proprietary Radiation Reduction Platform At ISASS 2017

Posted On April 12, 2017 By OrthoSpineNews In Spine /  

SAN DIEGO, April 12, 2017 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced it will showcase the Company’s LessRay® software technology at the International Society for Advancement of Spine Surgery’s (ISASS) 17th annual conference held April 12-14, 2017 in Boca Raton, Florida.

LessRay is a proprietary image enhancement technology that improves low-quality, low-radiation images to look more like conventional full-dose images without disrupting surgical workflow. The software is designed to be integrated into current surgeon workflow and utilizes an algorithm to drive image registration and enable management of radiation exposure, while maintaining high-quality, intra-operative images on existing C-Arm workflow without loss of visual accuracy.

NuVasive ISASS17 Participation Details

NuVasive will showcase its technologies at NuVasive Booth #400 on the ISASS exhibit floor.

The Company will host an industry lunch workshop featuring Robert Isaacs, M.D. and LessRay on April 12, 2017 from 12:00 p.m. to 1:30 p.m. at Room Royal 7.

Visit here for more details and the schedule of events.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA™ platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com

Read More
mma.prnewswire.comHSS_Ambulatory_Surgery_Ce-2f9fe533a85ce996cd3674405f97a53377f77230.jpg

HSS Opens Ambulatory Surgery Center in Manhattan

Posted On April 12, 2017 By OrthoSpineNews In Extremities, Sports Medicine /  

NEW YORK, N.Y., April 12, 2017 /PRNewswire-USNewswire/ — Today, Hospital for Special Surgery (HSS) the first and only hospital in the United States dedicated to orthopedic and rheumatologic care, announced its plan to open the HSS ASC of Manhattan in June 2017.

The HSS ASC of Manhattan will focus on hand, foot and ankle and sports medicine surgeries. David S. Levine, MD, foot and ankle surgeon at HSS, will serve as the center’s medical director.

“The HSS ASC of Manhattan is a very exciting initiative,” said Dr. Levine. “This new location and offering will substantially expand access to ambulatory surgery as an extension of Hospital for Special Surgery.”

The 22,425 square-foot center is conveniently located at 1233 Second Avenue at 65th Street, a short distance from the Hospital main campus. The center features four operating rooms and a 16 bay pre- and post-surgical unit.

“For nearly three decades HSS has been leading the fields of orthopedics and rheumatology in quality and patient experience,” said Louis A. Shapiro, president and CEO, Hospital for Special Surgery. “HSS is more than a hospital and we’re constantly working to identify news ways to make better quality care more accessible, through research, innovation and locations like this new ASC.”

Bryan Guss, RN, BSN, CNOR, will be the new senior director of the ASC and is joining HSS from Northern Westchester Hospital. HSS physicians on staff at the ASC will include ten sports medicine specialists, five foot and ankle surgeons and five hand and upper extremity surgeons. In addition to the 20 specialty surgeons, there will be anesthesiologists and nursing professionals providing care to patients.

Ambulatory surgery cases will still be performed at the HSS main campus. The HSS ASC of Manhattan is optimizing the care delivery system by providing another surgical location option for patients.

About Hospital for Special Surgery
Hospital for Special Surgery (HSS) is the world’s leading academic medical center focused on musculoskeletal health. HSS is nationally ranked No. 1 in orthopedics and No. 2 in rheumatology by U.S. News & World Report (2016-2017), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The Hospital’s research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. Hospital for Special Surgery is located in New York City and online at www.hss.edu.

 

SOURCE Hospital for Special Surgery

Related Links

http://www.hss.edu

Read More
10-years-joimax-China_Pic-for-PR-1.jpg

joimax® Celebrates Its 10th Anniversary with 900 Users in China and Reports a Jump in Q1-2017 Sales

Posted On April 12, 2017 By OrthoSpineNews In Financial, Spine /  

April 11, 2017

IRVINE, Calif.–(BUSINESS WIRE)–joimax®, the German-based market leader of technologies and training methods for endoscopic minimally invasive spinal surgery, recently celebrated its 10-year anniversary in China with an outstanding 3-day event in Chongqing. More than 900 surgeons out of 2,000 users in China took part in live surgeries, workshops and a scientific program on endoscopic spinal technologies including MISS fusion techniques. joimax® also organized the presentation of its latest systems like the TESSYS® ISeeU and iLESSYS® Delta in product trainings as well as its newest tools for endoscopic treatment in an exhibition hall. The program was supported by joimax® Faculty Members from Europe, USA and other countries.

During the meeting a Chinese Faculty Team, with 13 members, was inaugurated by Wolfgang Ries, Founder and CEO of joimax®, and Qin-Guang You, President of joimax® China. “Due to the growing education and training needs in the Asian region the time has come to form a local team for this important market,” explains Wolfgang Ries. “It is a great honor to lead this team and to support the further growth of joimax®,” says the head of the Faculty Team, Prof. Yue Zhou from the Third Military Medical University in Chongqing. He was awarded with the joimax® Handshake Award in Gold for his exceptional commitment, and the members of the group received the joimax® Handshake Award in Silver.

After growing sales figures in 2016 (31% growth vs. 2015), joimax® is proud to announce a jump in sales in the first quarter 2017. Consolidated figures show an increase of 60% compared to the same period of last year. “This is a very encouraging development, showing the continuing expansion and growth of the group,” states Wolfgang Ries, Founder and CEO of joimax®.

About joimax®

Founded in Karlsruhe, Germany, in 2001, joimax® is the leading developer and marketer of complete systems for endoscopic minimally invasive spinal surgery. With TESSYS® (transforaminal), iLESSYS® (interlaminar) and CESSYS® (cervical) for decompression procedures, MultiZYTE® RT (e.g. for rhizotomy) and with MultiZYTE® SI for SI-Joint therapy or with EndoLIF® and Percusys® for endoscopic minimally-invasive assisted stabilizations, proven endoscopic systems are provided that, together, cover a whole variety of indications.

In procedures for herniated disc, stenosis, pain therapy or spinal stabilization treatment, surgeons utilize joimax® technologies to operate through small incisions – under local or full anesthetic – via tissue and muscle-sparing corridors through natural openings into the spinal canal (e.g. intervertebral foramen, the “Kambin triangle”).

Contacts

Press Contact USA:
joimax® Inc.
Melissa Brumley
001 949 859 3472
Melissa.brumley@joimaxusa.com

Read More